FDA: Hospira recalls four lots of Labetalol Hydrochloride
Editor's Note
The Food and Drug Administration (FDA) on February 23 announced the recall by Hospira Inc (Lake Forest, Illinois) of three lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL vial (NDC 0409-2267-25), and one lot of Labetalol Hydrochloride Injection, USP, Novaplus (NDC 0409-2267-25).
The recall was initiated because of the discovery of cracks on the rim surfaces of vials in these lots. Cracked vials may result in a lack of sterility assurance.
The lots were distributed nationwide from April 2017 to August 2017.
Posted 02/23/2018] AUDIENCE: Pharmacy, Risk Manager, Nursing ISSUE: Hospira is voluntarily recalling 3 lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial (NDC 0409-2267-20), and one lot of Labetalol Hydrochloride Injection, USP, Novaplus (NDC 0409-2267-25) to the hospital/institution level. Hospira, Inc.
Free Daily News
- Hospital addresses barriers to patient rest, recovery
- Study: Psilocybin therapy reduces depression in frontline clinicians
- Exclusive articles preview OR Business Management Conference sessions
- Study: Surgeries improve survival in young BRCA-positive breast cancer patients
- Study: Advanced recovery room care could reduce long-term postoperative mortality
- FDA designates Class 1 recalls for balloon catheters, radiographic markers
- Orthopedic surgery in 2025: Embracing innovation, preserving autonomy
- Medtronic, Zimmer Biomet challenge Intuitive Surgical’s robotic surgery dominance
- Anthem’s anesthesia time limit policy, reversal sparks new legislation
- Simple procedure or ‘surgery’? Questionable medical billing practices cause confusion